Loading

Ocugen

June 16, 2025
Company Presentation
Ophthalmology
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
Ocugen
Company HQ City: Malvern
Company HQ State: PA
Company HQ Country: United States
Year Founded: 2013
Lead Product in Development: OCU-400

CEO

Dr. Shankar Musunuri

Development Phase of Lead Product

Phase III

Exchange

NASDAQ

Ticker

OCGN

When you expect your next catalyst update?

Initiate OCU410ST Phase 2/3 pivotal confirmatory clinical trial

What is your next catalyst (value inflection) update?

mid-2025
Visit Website
Primary Speaker
Shankar Musunuri
Shankar Musunuri, PhD
Chairman, CEO, Co-founder
Ocugen

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS